Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

OVID vs PLUR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

OVID Wins Head-to-Head Institutional Verdict (4–1 across 6 Pillars · 7–2 Matrix Metrics)

OVID Overall Winner 6-Pillar Tally: OVID 4 – 1 PLUR (1 Tie) Matrix Metrics: OVID 7 – 2 PLUR

As of Nov 17, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). OVID carries a Unified Composite Score of 52.3/100 (HOLD) at $2.19 (1.8x Forward P/E, -4693.7% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin).

  • Growth vs. Quality Trade-Off: OVID earns the overall head-to-head edge with a stronger Unified Composite Score (52.3/100 HOLD vs. PLUR 28.8/100 SELL) and 1.06β · 99% Vol risk profile, whereas PLUR leads top-line expansion (-15.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: OVID is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OVID vs PLUR
OVID NASDAQ Head-to-Head Winner
Ovid Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$2.19
-8.54% 1D
Market Cap $479.4M
TTM Revenue $1.5M
Forward P/E 1.8x
Beta / 30D Vol 1.06β · 99% Vol
Unified Composite Score
52.3 / 100 HOLD
Tech 29.0 Fund 48.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.4%), weak momentum, RSI 41
RSI-14: 41.4 · SMA20: $2.51 · SMA50: $2.49
PLUR US Equity
Pluri Inc.
Biological Products, (No Diagnostic Substances)
$0.94
-9.19% 1D
Market Cap $15.1M
TTM Revenue $1.0M
Forward P/E 3.6x
Beta / 30D Vol 0.80β · 102% Vol
Unified Composite Score
28.8 / 100 SELL
Tech 15.0 Fund 34.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -13.4%), weak momentum, RSI 40
RSI-14: 39.9 · SMA20: $1.14 · SMA50: $1.08

6-Pillar Scorecard Institutional Category Breakdown (OVID 4 – 1 PLUR)

Columns: Metric · OVID · PLUR
1. Valuation Multiples OVID
Forward P/E 1.8x 3.6x
Trailing P/E 1.8x 3.6x
PEG Ratio N/M N/M
EV / Revenue N/M 44.6x
2. Growth & Scale PLUR
Revenue Growth (YoY) -88.3% -15.8%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $1.5M $1.0M
Market Cap $479.4M $15.1M
3. Profitability & Quality OVID
Gross Margin 100.0% 44.6%
Operating Margin -4693.7% -2454.5%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -35.4% -1022.0%
4. Balance Sheet & Cash Flow OVID
Cash Generation (TTM) -$58M -$22M
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.5M Net Cash $30M Net Debt
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OVID
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 131.0% (30th %ile) N/A (N/A)
Put/Call OI Skew 0.06x (Call-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OVID (7) vs PLUR (2)
Institutional Metric OVID PLUR Criterion Row Edge
Market Capitalization
Scale
$479.4M $15.1M Larger Scale OVID
Trailing P/E Ratio
Valuation
1.8x 3.6x Lower Multiple OVID
Forward P/E Ratio
Valuation
1.8x 3.6x Lower Multiple OVID
Revenue Growth (YoY)
Growth
-88.3% -15.8% Higher Growth PLUR
Operating Margin (TTM)
Profitability
-4693.7% -2454.5% Higher Margin PLUR
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-35.4% -1022.0% Higher ROE OVID
52-Week Range Position
Momentum
53% ($1–$3) 2% ($1–$5) Stronger Trend OVID
Beta / 30D Volatility
Risk Regime
1.06β · 99% Vol 0.80β · 102% Vol Lower Realized Risk OVID
Unified Institutional Score
Composite Signal
52.3 / 100 (HOLD) 28.8 / 100 (SELL) Higher Composite OVID
Trailing 12M Revenue (USD)
Operating Scale
$1.5M $1.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% 44.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 44.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$58M ($1.5M Net Cash) -$22M ($30M Net Debt) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PLUR +9.94 pp
OVID: +1.15% · PLUR: +11.09%
3M Horizon OVID +21.25 pp
OVID: -25.09% · PLUR: -46.34%
6M Horizon OVID +53.98 pp
OVID: -8.54% · PLUR: -62.52%
1Y Horizon OVID +143.73 pp
OVID: +68.2% · PLUR: -75.53%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period OVID Revenue PLUR Revenue OVID Op. Margin PLUR Op. Margin Margin Leader
FY2019 N/A $0M N/A -65800.0% PLUR
FY2020 $10M $0M -645.4% -128156.5% OVID
FY2021 $210M N/A 59.6% N/A OVID
FY2022 $0M $0M -3696.4% -17774.8% OVID
FY2023 $0M $0M -15122.7% -9493.4% PLUR
FY2024 $0M $0M -10933.7% -6796.9% PLUR
FY2025 $10M $0M -585.2% -1659.9% OVID
FY2026 N/A $0M N/A -2454.5% PLUR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OVID CONSOLIDATION
151d in phase · OBV DISTRIBUTION
Current IV 131.0%
IV Percentile 30th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact OVID Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PLUR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PLUR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OVID Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $479.4M market capitalization and -4693.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PLUR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.1M market capitalization and -2454.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OVID vs PLUR Key Questions & Quantitative Answers

As of Nov 17, 2026, Ovid Therapeutics Inc. (OVID) is the stronger overall head-to-head candidate over Pluri Inc. (PLUR) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 4–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). OVID carries a Unified Composite Score of 52.3/100 (HOLD) at $2.19 (1.8x Forward P/E, -4693.7% operating margin), whereas PLUR carries 28.8/100 (SELL) at $0.94 (3.6x Forward P/E, -2454.5% operating margin). Growth vs. Quality Trade-Off: OVID earns the overall head-to-head edge with a stronger Unified Composite Score (52.3/100 HOLD vs. PLUR 28.8/100 SELL) and 1.06β · 99% Vol risk profile, whereas PLUR leads top-line expansion (-15.8% YoY revenue growth, N/M PEG, and 1 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: OVID is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.4); meanwhile PLUR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PLUR leads the Growth & Scale pillar: OVID posts -88.3% YoY revenue growth and +0.0% YoY earnings growth on $1.5M TTM revenue (100.0% gross margin, -4693.7% operating margin), compared with PLUR at -15.8% YoY revenue growth and +0.0% YoY earnings growth on $1.0M TTM revenue (44.6% gross margin, -2454.5% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), OVID cumulative revenue shifted +0.0% while PLUR shifted N/A. In operating R&D and SG&A reinvestment, OVID deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PLUR.

OVID screens cheaper on headline valuation multiples. OVID trades at 1.8x Forward P/E, 1.8x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PLUR trades at 3.6x Forward P/E, 3.6x Trailing P/E, N/M PEG, and 44.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OVID (-35.4% ROE) versus PLUR (-1022.0% ROE) capital efficiency.

In options market volatility and institutional positioning, OVID carries 131.0% implied volatility (30th %ile, Balanced (25th–60th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.06β · 99% Vol realized risk). By comparison, PLUR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.80β · 102% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.